Vaccine Info

Flulaval Quadrivalent Influenza Vaccine

Authored by

Staff

Last reviewed

June 14, 2021

Fact checked by

Robert Carlson, MD + Holly Lutmer PharmD

Flulaval Quadrivalent Influenza Vaccine Description

Flulaval Quadrivalent is a quadrivalent, split-virion, inactivated influenza virus vaccine prepared from virus propagated in the allantoic cavity of embryonated hens’ eggs. Each of the influenza viruses is produced and purified separately. The virus is inactivated with ultraviolet light treatment followed by formaldehyde treatment, purified by centrifugation, and disrupted with sodium deoxycholate.

Flulaval Quadrivalent contains thimerosal.

Flulaval for 2021-2022, quadrivalent (four-component) egg-based vaccines are recommended to contain:

A/Victoria/2570/2019 (H1N1)pdm09-like virus
A/Cambodia/e0826360/2020 (H3N2)-like virus
B/Washington/02/2019 (B/Victoria lineage)-like virus
B/Phuket/3073/2013 (B/Yamagata lineage)-like virus

Flulaval Quadrivalent Influenza Vaccine Indication

Flulaval Quadrivalent is indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.

Flulaval Quadrivalent Influenza Vaccine Dosage

Flulaval Quadrivalent is approved for use in persons aged 6 months and older.

Flulaval Quadrivalent is administered as an intramuscular injection.

For detailed dosage information visit GSK.

Flulaval Quadrivalent Influenza Vaccine News

July 28, 2020 - GSK begins shipping a record number of its influenza vaccine doses for the 2020-21 season for the US market. FLULAVAL QUADRIVALENT will be available in a 0.5mL, single-dose, pre-filled syringe, and indicated for patients 6 months and older in line with CDC recommendations.

November 18, 2016 - GSK announced it has received approval from the US Food and Drug Administration’s (FDA) Center expanding the indication for FluLaval® Quadrivalent (Influenza Vaccine) to include use in children 6 months and older. Prior to this, the vaccine was only approved for active immunization against influenza A subtype viruses and type B viruses, in persons 3 years of age and older.